Dr Tombal presents the agenda for a discussion on prostate cancer treatment options at ESMO 2014.
From the same symposium:
Understanding PC heterogeneity to guide treatment choices
Optimizing survival in advanced prostate cancer: Tailoring mCRPC therapies to optimise survival
CHAARTED: What are the implications for the future?